Clinical Trial: A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors

U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07229612) titled 'A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors' on Nov. 13.

Brief Summary: This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Malignant Solid Tumors

Intervention: DRUG: SHR-4298 Injection

SHR-4298 injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....